 Fluorouracil
"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 5 | 8 | 13 | | 1991 | 1 | 11 | 12 | | 1992 | 5 | 16 | 21 | | 1993 | 4 | 10 | 14 | | 1994 | 3 | 13 | 16 | | 1995 | 7 | 17 | 24 | | 1996 | 4 | 9 | 13 | | 1997 | 4 | 19 | 23 | | 1998 | 7 | 26 | 33 | | 1999 | 9 | 24 | 33 | | 2000 | 6 | 21 | 27 | | 2001 | 4 | 25 | 29 | | 2002 | 4 | 17 | 21 | | 2003 | 11 | 31 | 42 | | 2004 | 13 | 33 | 46 | | 2005 | 7 | 37 | 44 | | 2006 | 6 | 46 | 52 | | 2007 | 10 | 35 | 45 | | 2008 | 7 | 24 | 31 | | 2009 | 7 | 40 | 47 | | 2010 | 7 | 27 | 34 | | 2011 | 5 | 25 | 30 | | 2012 | 2 | 26 | 28 | | 2013 | 8 | 22 | 30 | | 2014 | 4 | 28 | 32 | | 2015 | 2 | 18 | 20 | | 2016 | 6 | 16 | 22 | | 2017 | 4 | 25 | 29 | | 2018 | 1 | 9 | 10 | | 2019 | 4 | 10 | 14 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Cochrane Database Syst Rev. 2020 03 12; 3:CD009498.
-
Rogers JE, Xiao L, Trail A, Blum Murphy M, Palmer M, Ajani JA. Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.
-
Rivin Del Campo E, Matzinger O, Haustermans K, Peiffert D, Glynne-Jones R, Winter KA, Konski AA, Ajani JA, Bosset JF, Hannoun-Levi JM, Puyraveau M, Chakravarthy AB, Meadows H, Northover J, Collette L, Christiaens M, Maingon P. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019 11; 121:130-143.
-
Bozkurt M, Antonoff M, Jaramillo S, Sagebiel T, Murphy MB. Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature. J Gastrointest Cancer. 2019 09; 50(3):634-640.
-
Rogers JE, Ajani JA. Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. J Clin Oncol. 2019 10 20; 37(30):2805-2806.
-
Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019 09; 119:87-96.
-
Zhang Z, Zhou Z, Zhang M, Gross N, Gong L, Zhang S, Lei D, Zeng Q, Luo X, Li G, Li X. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment. Biomed Pharmacother. 2019 Oct; 118:109306.
-
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794.
-
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
-
Vreeland TJ, McAllister F, Javadi S, Prakash LR, Fogelman DR, Ho L, Varadhachary G, Aloia TA, Vauthey JN, Lee JE, Kim MP, Katz MHG, Tzeng CD. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|